A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease.

Authors	Adriana Prundean, Katia Youssov, Sandrine Humbert, Dominique Bonneau, Christophe Verny
Journal	Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 30 Issue 2 Pg. 288-9 (Feb 2015) ISSN: 1531-8257 [Electronic] United States
PMID	25475049 (Publication Type: Clinical Trial, Phase II, Letter)
Chemical References	Cysteamine
Topics	Adolescent Adult Cysteamine (administration & dosage, adverse effects, therapeutic use) Drug Tolerance Humans Huntington Disease (drug therapy) Middle Aged Treatment Outcome Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!